STAT1-GSDME焦亡回路的药理学激活强化肝细胞癌的表观遗传免疫治疗
本研究通过单细胞RNA测序分析帕博利珠单抗试验(NCT03419481)中肝细胞癌患者的HDAC亚型表达与预后关系,发现HDAC1/2/3高表达者IFNγ信号缺陷且免疫检查点阻断(ICB)疗效差;选择性I类HDAC抑制剂CXD101可重新致敏HDAC1/2/3高表达肿瘤,机制涉及STAT1驱动的抗肿瘤免疫和GSDME介导的焦亡。
要点
- HDAC1/2/3高表达的肝细胞癌患者IFNγ信号缺陷且ICB治疗生存更差。
- CXD101短暂处理可重新致敏HDAC1/2/3高表达肿瘤对ICB的应答。
- CXD101与ICB协同通过STAT1-GSDME焦亡回路增强抗肿瘤免疫。
核心结论
- 免疫表观遗传策略利用IFNγ介导的网络增强肿瘤-免疫循环,揭示自我强化的STAT1-GSDME焦亡回路作为正在进行的II期试验(NCT05873244)解决ICB耐药性的机制基础。
研究设计与样本
- 研究将来自帕博利珠单抗试验(NCT03419481)的肝细胞癌患者预后与通过单细胞RNA测序检测的所有HDAC亚型肿瘤细胞表达进行关联。
- 在4个ICB耐药的原位和自发模型中研究选择性HDAC抑制的治疗疗效和作用机制,使用免疫谱分析、单细胞多组学和染色质免疫沉淀测序,并通过基因修饰和共培养系统验证。
主要发现
- HDAC1/2/3表达较高的肝细胞癌患者表现出缺陷的IFNγ信号和ICB治疗下较差的生存。
- 选择性I类HDAC抑制剂CXD101的短暂治疗重新致敏HDAC1/2/3高表达肿瘤对ICB治疗,导致CD8+T细胞依赖的抗肿瘤和记忆T细胞应答。
- CXD101与ICB协同通过增强IFNγ响应基因的染色质可及性和H3K27超乙酰化刺激STAT1驱动的抗肿瘤免疫。
- IFNγ+GZMB+细胞毒性淋巴细胞在肿瘤内的募集进一步促进CXD101诱导的Gasdermin E(GSDME)切割,以STAT1依赖的方式触发焦亡。
- GSDME缺失模拟STAT1敲除,通过阻断焦亡和IFNγ应答 abolish CXD101-ICB联合治疗的抗肿瘤疗效和生存获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic screening uncovered interferon-gamma (IFNγ) pathway defects in tumours refractory to immune checkpoint blockade (ICB). However, its non-mutational regulation and reversibility for therapeutic development remain less understood. OBJECTIVE: We aimed to identify ICB resistance-associated druggable histone deacetylases (HDACs) and develop a readily translatable combination approach for patients with hepatocellular carcinoma (HCC). DESIGN: We correlated the prognostic outcomes of HCC patients from a pembrolizumab trial (NCT03419481) with tumourous cell expressions of all HDAC isoforms by single-cell RNA sequencing. We investigated the therapeutic efficacy and mechanism of action of selective HDAC inhibition in 4 ICB-resistant orthotopic and spontaneous models using immune profiling, single-cell multiomics and chromatin immunoprecipitation-sequencing and verified by genetic modulations and co-culture systems. RESULTS: HCC patients showing higher HDAC1/2/3 expressions exhibited deficient IFNγ signalling and poorer survival on ICB therapy. Transient treatment of a selective class-I HDAC inhibitor CXD101 resensitised HDAC1/2/3high tumours to ICB therapies, resulting in CD8+T cell-dependent antitumour and memory T cell responses. Mechanistically, CXD101 synergised with ICB to stimulate STAT1-driven antitumour immunity through enhanced chromatin accessibility and H3K27 hyperacetylation of IFNγ-responsive genes. Intratumoural recruitment of IFNγ+GZMB+cytotoxic lymphocytes further promoted cleavage of CXD101-induced Gasdermin E (GSDME) to trigger pyroptosis in a STAT1-dependent manner. Notably, deletion of GSDME mimicked STAT1 knockout in abolishing the antitumour efficacy and survival benefit of CXD101-ICB combination therapy by thwarting both pyroptotic and IFNγ responses. CONCLUSION: Our immunoepigenetic strategy harnesses IFNγ-mediated network to augment the cancer-immunity cycle, revealing a self-reinforcing STAT1-GSDME pyroptotic circuitry as the mechanistic basis for an ongoing phase-II trial to tackle ICB resistance (NCT05873244).
引用
- Tu Y, Wu H, Zhong C, et al. Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. Gut. 2025. PMID: 39486886. doi:10.1136/gutjnl-2024-332281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。